AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00107237
Drug: AEE788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
Trial: NCT00959816
Drug: ABT-614
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
Trial: NCT01670890
Drug: TMZ plus CDDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
Trial: NCT00100464
Drug: 5HTP
RxNorm normalized name: GABA/5HTP/caf/arg/chl/br/hb318 1,400 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03557281
Drug: GSK3036656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3036656 will be administered
Trial: NCT04080375
Drug: Dinoprostone 3 mg
RxNorm normalized name: dinoprostone 3 MG
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
Trial: NCT00891605
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Trial: NCT04080375
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patient will take one vaginal tablet of placebo 1 hour before surgery
Trial: NCT03378076
Drug: FX006 32 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
Trial: NCT03378076
Drug: TAcs 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
Trial: NCT02908516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 1.95 g cellulose orally, once in the ED and another dose pre-operatively.
Trial: NCT02438709
Drug: COX-2 inhibitor
RxNorm normalized name: COX-2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral COX-2 inhibitor intake 60mg qd
Trial: NCT04677712
Drug: CCH-aaes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were administered CCH-aaes by subcutaneous injection to both buttocks.
Trial: NCT04677712
Drug: INhance®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants used INhance Post-injection Serum topically immediately after the CCH-aaes injection to the right buttock.
Trial: NCT02995720
Drug: Fimasartan/Amlodipine combination drug, Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01726348
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
Trial: NCT02368717
Drug: Placebo Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03756038
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
Trial: NCT00783094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily
Trial: NCT02469090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00152542
Drug: Inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
Trial: NCT00152542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No iNO given for days 1-7
Trial: NCT00466401
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02261727
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor
Trial: NCT02261727
Drug: Placebo (for prednisone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~* Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily
Trial: NCT02261727
Drug: Placebo (for Theophylline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
Trial: NCT03239821
Drug: Codeine Phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 58.8 mg codeïne phosphate
Trial: NCT03239821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirupus Simplex
Trial: NCT02057315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of matching placebo over 3 bilateral applications.
Trial: NCT03934450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
Trial: NCT00207688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
Trial: NCT01388738
Drug: L-Alpha glycerylphosphorylcholine
RxNorm normalized name: L-alpha-Glycerophosphorylcholine
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: choline alfoscerate IV 1000mg daily 10 days
Trial: NCT00969449
Drug: Naprelan, (BAY H6689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of Naprelan 500 mg (2 tablets) under fasting conditions
Trial: NCT02429440
Drug: Granulocyte Macrophage Colony Stimulating Factor
RxNorm normalized name: Granulocyte macrophage colony stimulating factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradermal
Trial: NCT00397826
Drug: MK0733
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 12 Weeks
Trial: NCT01952951
Drug: Capecitabine Oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
Trial: NCT02911714
Drug: Lumason Contrast-Enhanced Ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.
Trial: NCT00016887
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02972255
Drug: RO7079901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7079901 will be administered as per schedule described in individual arm.
Trial: NCT01120496
Drug: 3% hypertonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
Trial: NCT01120496
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
Trial: NCT00457925
Drug: GSK221149A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00840476
Drug: Meloxicam 15 mg Tablets
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 15 mg, single-dose fasting
Trial: NCT02776488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of normal saline
Trial: NCT00006366
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00909311
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, QD, 1 dose in each cross-over period
Trial: NCT00835263
Drug: Lamictal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Tablet
Trial: NCT01789970
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Trial: NCT01789970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Trial: NCT02112370
Drug: Ropivacaine with epinephrine injection
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
Trial: NCT03334175
Drug: Walnuts
RxNorm normalized name: WALNUTS,GRANULATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
Trial: NCT01399580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
Trial: NCT01839344
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral single dose of a solid, colored empty capsule.
Trial: NCT00003035
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02925130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute oral intake of a placebo drug
Trial: NCT01447017
Drug: DPK-060
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
Trial: NCT01447017
Drug: Placebo for DPK-060 ear drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
Trial: NCT01612260
Drug: placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 granules t.i.d. po for 12 weeks
Trial: NCT00578526
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
Trial: NCT00578526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg capsule OD PO for 28 days then 14 days rest until disease progression
Trial: NCT02127190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01576692
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy may include the following at the dosages shown below:~* cyclophosphamide: 400 mg/m\^2 IV days 1-5~* topotecan: 1.2 mg/m\^2 IV days 1-5~* temozolomide: 150 mg/m\^2 PO at least 1 hour before irinotecan~* irinotecan: 50 mg/m\^2 IV over 1 hour daily for 5 days~* carboplatin (AUC 8-dosing based on GFR), IV day 1 only~* ifosfamide: 2 g/m2 IV days 1-3~* etoposide: 100 mg/m2 days 1-3
Trial: NCT01999803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04898556
Drug: Prasterone 6.5 MG
RxNorm normalized name: prasterone 6.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose to be applied will be one Intrarosa ovule (Prasterone 6.5mg) a day before going to bed for 12 weeks.
Trial: NCT03350217
Drug: Eleview
RxNorm normalized name: Eleview Submucosal Injectable Composition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
Trial: NCT00285805
Drug: response (sodium excretion) to amiloride infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01496612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00830362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered once
Trial: NCT01087645
Drug: NN9925 (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
Trial: NCT01087645
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
Trial: NCT01087645
Drug: NN9925 (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
Trial: NCT01087645
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to receive a single dose of placebo
Trial: NCT00545662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
Trial: NCT01028586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets
Trial: NCT01420744
Drug: 1% Human Albumin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.~Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.~Treatment will be administered over a 5-day period.~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)
Trial: NCT03702218
Drug: Direct Acting Antivirals
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30
Trial: NCT01103713
Drug: Azithromycin plus chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
Trial: NCT01501253
Drug: CKD-828 2.5/40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
Trial: NCT01501253
Drug: CKD-828 2.5/80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
Trial: NCT00828659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828659
Drug: Active Comparator #1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828659
Drug: Active Comparator #2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00828659
Drug: Active Comparator #3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03099486
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
Trial: NCT00374244
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: half of the subjects are randomized to placebo group
Trial: NCT03280979
Drug: rescue regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
Trial: NCT00584870
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral naproxen 500 mg twice daily for Weeks 1-12.
Trial: NCT00584870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
Trial: NCT03216356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: polyethylene glycol 3350 powder
Trial: NCT03216356
Drug: Study Pill
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
Trial: NCT00727493
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
Trial: NCT01169558
Drug: Fluoropyrimidine-based Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoropyrimidine-based chemotherapy administered according to standard of care.
Trial: NCT00592111
Drug: COPP/ABV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 courses of COPP/ABV hybrid
Trial: NCT00592111
Drug: COPP/ABV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 courses of COPP/ABV hybrid
Trial: NCT03542669
Drug: 6B11-OCIK Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.
Trial: NCT03542669
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be adminitered 4\~6 cycles of chemotherapy (Doxorubicin, 30 mg/m\^2 IV on Day 1 of every cycle)
Trial: NCT00242554
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00484497
Drug: cyclamax
RxNorm normalized name: cyclamate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03398577
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
Trial: NCT02436876
Drug: MBN-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBN-101 is a locally administered, anti-infective drug product
Trial: NCT02995109
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z11-004)
Trial: NCT02995109
Drug: SPF Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Trial: NCT01447719
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
Trial: NCT01881165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no